<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: In the UK, oesophagectomy is the current recommendation for patients with persistent high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Radiofrequency ablation is an alternative new technology with promising early trial results </plain></SENT>
<SENT sid="2" pm="."><plain>AIM: To undertake a cost-utility analysis comparing these two strategies </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We constructed a Markov model to simulate the natural history of a cohort of patients with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> undergoing one of two treatment options: (i) oesophagectomy or (ii) radiofrequency ablation followed by endoscopic surveillance with oesophagectomy for high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> recurrence or persistence </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In the base case analysis, radiofrequency ablation dominated as it generated 0.4 extra quality of life years at a cost saving of £1902 </plain></SENT>
<SENT sid="5" pm="."><plain>For oesophagectomy to be the most cost-effective option, it required a radiofrequency ablation treatment failure rate (high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> persistence or progression to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>) of &gt;44%, or an annual risk of high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> recurrence or progression to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in the ablated oesophagus of &gt;15% per annum </plain></SENT>
<SENT sid="6" pm="."><plain>There was an 85% probability that radiofrequency ablation remained cost-effective at the NICE willingness to pay threshold range of £20 000-30 000 </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: Radiofrequency ablation is likely to be a cost-effective option for high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> in the UK </plain></SENT>
</text></document>